However, Chen et al.8 noted that most BET inhibitors do not distinguish between different BET proteins, and urged caution in the therapeutic use of pan-BET inhibitors in people at risk for COVID-19, concluding that “a molecule that specifically inhibits BRD2 but not BRD4 could be useful”. This evidence concerns the gene DNER and COVID-19.